Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa

Table 3 Immunological and virological response to ART among all ART-naïve adolescents and perinatally infected adolescents (9-19 years) compared with that of young adults (20-28 years)

Characteristics	All ART-naïve adolescents N = 64	ART-naïve young adults N = 715	P-value†	ART-naïve perinatally-infected adolescents N = 31	P-value†
Baseline CD4 (cells/μL), median (IQR)	139 (62-198)	117 (59-170)	0.15	170 (78-228)	0.026
CD4 (cells/μL), median (IQR) change from baseline
16 weeks	220 (133.5-314)	121 (67-199)	0.0001	188.5 (126-322)	0.0004
32 weeks	195 (136-439)	155 (97-238)	0.0008	256 (172-487)	0.0002
48 weeks	373 (255-518)	187 (118-285)	0.0001	374 (242-631)	0.0002
Virological suppression*, n(%)
16 weeks	36 (97.3)	490 (89.6)	0.13	27 (100.0)	0.077
32 weeks	12 (37.5)	331 (75.1)	< 0.001	7 (28.0)	< 0.001
48 weeks	9 (27.3)	270 (63.1)	< 0.001	6 (24.0)	< 0.001

†The p values were compared with young adults and calculated using Wilcoxon rank-sum test for continuous variables and fishers exact test for binary variables.
*The denominators at 16 weeks for all ART-naïve adolescents, perinatally infected adolescents and young adults were 37, 27 and 547 respectively; at 32 weeks was 32, 25 and 440 respectively and at 48 weeks was 33, 25 and 427 respectively.

ISSN: 1471-2334